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Abstract
Background: Pregnancy-associated plasma protein-A2 (PAPP-A2) is consistently upregulated in the placentae of
pregnancies complicated by preeclampsia and fetal growth restriction. The causes and significance of this
upregulation remain unknown, but it has been hypothesized that it is a compensatory response to improve
placental growth and development. We predicted that, if the upregulation of PAPP-A2 in pregnancy complications
reflects a compensatory response, then deletion of Pappa2 in mice would exacerbate the effects of a gene deletion
previously reported to impair placental development: deficiency of matrix metalloproteinase-9 (MMP9).
Methods: We crossed mice carrying deletions in Pappa2 and Mmp9 to produce pregnancies deficient in one, both,
or neither of these genes. We measured pregnancy rates, number of conceptuses, fetal and placental growth, and
the histological structure of the placenta.
Results: We found no evidence of reduced fertility, increased pregnancy loss, or increased fetal demise in Mmp9−/−
females. In pregnancies segregating for Mmp9, Mmp9−/− fetuses were lighter than their siblings with a functional
Mmp9 allele. However, deletion of Pappa2 did not exacerbate or reveal any effects of Mmp9 deficiency. We
observed some effects of Pappa2 deletion on placental structure that were independent of Mmp9 deficiency, but
no effects on fetal growth. At G16, male fetuses were heavier than female fetuses and had heavier placentae with
larger junctional zones and smaller labyrinths.
Conclusions: Effects of Mmp9 deficiency were not exacerbated by the deletion of Pappa2. Our results do not provide
evidence that upregulation of placental PAPP-A2 represents a mechanism to compensate for impaired fetal growth.
Keywords: Placenta, Pregnancy, Preeclampsia, Intrauterine growth restriction, Pregnancy associated plasma protein,
Matrix metalloproteinase, Insulin-like growth factor
Background
Intrauterine growth restriction and preeclampsia
threaten the health and wellbeing of both the fetus and
the mother, affecting 5–7% of pregnancies and constitut-
ing leading causes of perinatal and maternal mortality
[1]. These conditions are thought to be caused, at least
in part, by abnormal placental development and function
[2]. There have been enormous efforts to identify the
molecular mechanisms responsible for placental dys-
function in preeclampsia and intrauterine growth restric-
tion, with numerous studies examining placental gene
expression at delivery. Pregnancy-associated plasma
protein-A2 (PAPP-A2) is one of the genes most consist-
ently found to be upregulated in preeclampsia [3–7] and
is also associated with fetal growth restriction [8]. Fur-
thermore, elevated levels of PAPP-A2 in the maternal
circulation in the first trimester have also been associ-
ated with preeclampsia [9, 10]. PAPP-A2 is a protease of
insulin-like growth factor binding protein 5 (IGFBP-5)
[11] and is thought to regulate insulin-like growth factor
(IGF) availability, although it may also function through
other pathways [12]. IGFs play key roles in placental de-
velopment [13], and their availability is regulated by six
IGF binding proteins (IGFBPs). IGFs are released pri-
marily through cleavage of the IGFBPs by proteases [14].
* Correspondence: julian_christians@sfu.ca
Department of Biological Sciences, Simon Fraser University, Burnaby, BC,
Canada
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Christians et al. Reproductive Biology and Endocrinology  (2018) 16:58 
https://doi.org/10.1186/s12958-018-0376-4
PAPP-A2 deficiency would therefore be expected to re-
duce IGF availability, and indeed loss-of-function muta-
tions in humans reduce stature [15] while Pappa2
deletion in mice reduces body size [16–18] and increases
IGFBP-5 levels [19].
Despite the high expression of PAPP-A2 in mouse pla-
centa [20], Pappa2 deletion has no effect on pregnancy
outcomes, apart from slightly reduced birthweight,
which may be due to deletion in the fetus itself [16, 21].
We therefore hypothesized that the upregulation of
PAPP-A2 in human pregnancy complications represents
a compensatory response to increase IGF signaling to
promote placental growth and development [10, 22, 23].
To test this hypothesis, we deleted Pappa2 in a mouse
model of preeclampsia and intrauterine growth restric-
tion: deficiency of matrix metalloproteinase-9 (MMP9)
[24]. We selected this model since Mmp9 deletion im-
pairs early placental development [24], and thus reflects
“canonical” preeclampsia, rather than preeclampsia of
other etiologies [25]. Deficiencies in early placental de-
velopment would be expected to be ameliorated by in-
creased IGF availability and, therefore, by increased
PAPP-A2 expression. We predicted that, if the elevated
expression of PAPP-A2 in preeclampsia in humans re-
flects a compensatory response, then deletion of Pappa2
in mice would exacerbate effects of Mmp9 deletion, i.e.,
mice null for both Pappa2 and Mmp9 would show a
more severe phenotype than mice null for Mmp9 only.
We focused on the number and size of fetuses, as well
as placental histology since these were traits expected to
be affected by Mmp9 deficiency [24] and potentially
ameliorated by PAPP-A2 and increased IGF availability.
Methods
All work was carried out in accordance with the guidelines
of the Canadian Council on Animal Care and approved by
the SFU University Animal Care Committee (protocol
1188B). Pappa2 deletion mice with a C57BL/6 back-
ground were generated as previously described [16, 19].
Females homozygous for Pappa2 deletion (Pappa2−/−)
were crossed with a male homozygous for Mmp9 deletion
(Mmp9−/−) obtained from the Jackson Laboratory (stock
number 007084) to produce offspring heterozygous at
both genes. The first generation (F1) offspring were
crossed to produce an F2 population that included mice
with all nine possible genotypes (three Mmp9 genotypes x
three Pappa2 genotypes). Females and males from the F2
population were selected based on Mmp9 and Pappa2
genotype for breeding experiments, and were mated as de-
scribed in Table 1. Rather than using only homozygous
mice, we performed a variety of crosses to make use of as
many mice as possible (Table 1). Furthermore, mating
type 1 with Mmp9+/− males was previously reported to
show a reduction in litter size and placental abnormalities
[24]. Beginning at approximately 8 weeks of age, females
were placed with a male for one night, checked for vaginal
plugs, and removed from the male whether or not a plug
was observed. If no vaginal plug was observed and/or if fe-
male weight had not increased by ~ 1 g 1 week after mat-
ing, females were paired again. F2 females were collected
at day 16 of gestation (G16; where the day after mating =
day 0). To obtain mice for a further cohort, some females
heterozygous at both genes (Mmp9+/−; Pappa2+/−) were
paired with males homozygous for both deletions
(Mmp9−/−; Pappa2−/−) and not collected during preg-
nancy. We produced a backcross (BC) population, rather
than crossing heterozygotes, to increase the number of
mice homozygous for Mmp9 and/or Pappa2 deletion.
Females and males from the BC population were mated in
the same manner as the F2 population, except that
females were collected at day 18 of gestation (G18).
Pregnancies were sampled at G18 in case effects were ap-
parent only after G16. 63 F2 females were mated, yielding
43 G16 pregnancies (although one was mistakenly not col-
lected during pregnancy) whereas 24 BC females were
mated, yielding 20 G18 pregnancies.
At collection, females were blood sampled by cardiac
puncture and the entire uterus was placed in 4% formal-
dehyde solution in phosphate buffered saline for 3 days
before it was dissected to count and weigh individual fe-
tuses and placentae, and to count putative fetal resorp-
tions (green or green/brown masses). Maternal serum
vascular endothelial growth factor (VEGF) was measured
by enzyme-linked immunosorbent assay (R&D Systems,
MMV00). Fixed placentae were stored in 70% ethanol
until embedded in paraffin. A subset of placentae were
selected for sectioning, attempting to include one male
and one female placenta for each female, and excluding
heterozygous genotypes. Because previous work reported
that both embryonic and maternal Mmp9 deficiency
affect placental development [24], we selected Mmp9−/−
placentae from both Mmp9−/− and Mmp9+/− dams, as
well as Mmp9+/+ placentae from Mmp9+/+ dams. For
each placenta, multiple sections (6 μm) were obtained ~
440 μm apart, up to a maximum of 10 sections per pla-
centa. Sections were stained with haematoxylin and
eosin and the areas of the labyrinth, junctional zone and
Table 1 Mmp9 crosses performed in experiments
Mating type Female MMP9 genotype Male MMP9 genotype
0 −/− −/−
1 −/− +/−
2 +/− −/−
3 +/− +/−
4 +/+ +/+
Each type of Mmp9 cross included either no functional Pappa2 alleles
(Pappa2−/− x Pappa2−/−) or at least one functional Pappa2 (achieved with
various combinations of female and male genotype)
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decidua were measured using ImageJ 1.48v. Damaged
sections, and sections close to the edge of the placenta
(i.e., where the labyrinth was mostly surrounded by junc-
tional zone) were excluded, yielding 454 sections from
62 placentae (average: 7.3 sections per placenta). To ob-
tain a single value for each of the labyrinth, junctional
zone and decidua for each placenta, we analysed the
areas from all 454 sections using a general linear model
(proc GLM, SAS, Version 9.4) including terms for pla-
centa identity and section location (i.e., close to the
centre vs. further from the centre; sections further from
the centre had smaller areas). From this analysis, we ob-
tained the least squares mean for each placenta for each
of the labyrinth, junctional zone and decidua.
To obtain tissue for genotyping, mice were ear-clipped
at weaning or a small section of fetal tail was collected.
Pappa2 genotype [19] and fetal sex [26] were deter-
mined as previously described. Mmp9 genotype was de-
termined by PCR as recommended by the Jackson
Laboratory (primers used: 5’-CTGAATGAACTGCA
GGACGA-3′; 5’-ATACTTTCTCGGCAGGAGCA-3′;
5’-GTGGGACCATCATAACATCACA-3′; 5’-CTCG
CGGCAAGTCTTCAGAGTA-3′;).
All statistical analyses were performed using general
linear models (proc GLM) or repeated measures analyses
(proc MIXED) in SAS, Version 9.4 (SAS Institute Inc.,
Cary, NC). Repeated measures analyses (with dam as a
random factor) were used for placental and fetal traits
where there were multiple offspring per dam, since the
dam was the unit of replication.
Results
The genotype ratios and postnatal growth of the F2 and
BC populations are presented in the Additional file 1.
Combining F2 and BC females, we found no evidence of
reduced fertility or increased pregnancy loss in Mmp9−/−
females. The proportion of females that became preg-
nant did not differ between Mmp9−/− females and other
females, whether all females were analysed together
(Fisher’s Exact Test P = 0.47) or separately based on
whether at least one wild-type Pappa2 allele was present
(Fisher’s Exact Test P = 1.00) or not (Fisher’s Exact Test
P = 0.27) (Table 2). Similarly, the proportion of females
that had at least one failed mating (i.e., a vaginal plug
was detected following mating, but pregnancy did not
develop) did not differ between Mmp9−/− females and
other females. This was true whether all females were
analysed together (Fisher’s Exact Test P = 0.47) or separ-
ately based on whether at least one wild-type Pappa2 al-
lele was present (Fisher’s Exact Test P = 0.33) or not
(Fisher’s Exact Test P = 1.00) (Table 2). The number of
times a female was paired with a male before becoming
pregnant did not differ between Mmp9−/− and other fe-
males (F1,59 = 0.18; P = 0.67), and was not affected by
whether at least one wild-type Pappa2 allele was present
(F1,59 = 2.22; P = 0.14), or by the interaction between
these two factors (F1,59 = 0.10; P = 0.76) (Table 2). Since
the number of times a female was paired with a male
varied only from 1 to 6, we also analysed these data
using a non-parametric Wilcoxon test. Again there was
no difference between Mmp9−/− and other females (P =
0.71), pooling matings with and without at least one
wild-type Pappa2 allele present.
We also found no evidence of reduced fecundity or in-
creased fetal loss in Mmp9−/− females. Including females
collected at either G16 or G18, the number of fetuses
did not differ between Mmp9−/− and other females
(F1,58 = 0.28; P = 0.60), and was not affected by whether
at least one wild-type Pappa2 allele was present (F1,58 =
0.00; P = 0.99) or the interaction between these two fac-
tors (F1,58 = 0.17; P = 0.68) (Fig. 1). The number of puta-
tive embryo resorptions ranged from 0 to 4, and tended
to be slightly lower in Mmp9−/− females (mean = 0.6)
than in other females (mean = 0.9; Wilcoxon test P =
0.25). The proportion of females that had at least one re-
sorption did not differ between Mmp9 genotypes (11/30
Mmp9−/− females vs. 16/32 other females; Fisher’s Exact
Test P = 0.32).
At G16, the average fetal mass and average placental
mass did not differ between Mmp9−/− and other females,
Table 2 Effects of Mmp9 and Pappa2 deletion on fertility including F2 and BC females, i.e., females collected at G16 or G18
No wild-type Pappa2 alleles
Mmp9 mating type
At least one wild-type Pappa2 allele
Mmp9 mating type
0–1 2–4 0–1 2–4
# matings for pregnancya 2.3 ± 0.4 2.3 ± 0.3 2.7 ± 0.3 2.9 ± 0.3
# females that became pregnant 11 16 19 17
# females that did not become pregnant 2 9 7 6
# females with no failed matingsb 9 18 18 19
# females with failed matingb 4 7 8 4
aLeast-squares means ± standard error from a general linear model including Mmp9 mating type, whether mating had any wild-type Pappa2 alleles, and the
interaction between these two terms
bA failed mating was defined as when a vaginal plug was detected following mating, but pregnancy did not develop; this analysis includes females that
subsequently became pregnant, and those that never became pregnant
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and was not affected by whether at least one wild-type
Pappa2 allele was present or the interaction between these
two factors (controlling for the number of fetuses, which
was negatively related to fetal and placental mass; Table 3).
There was no excess of very small or runted pups in
Mmp9−/− pregnancies (Fig. 2). There was a tendency for
Mmp9−/− females to have heavier placentae, but this was
marginally non-significant (P = 0.07, Table 3). Considering
only pregnancies with both Mmp9+/− and Mmp9−/− fe-
tuses, Mmp9−/− fetuses and their placentae were signifi-
cantly lighter than their Mmp9+/− siblings, but there was
no effect of whether a wild-type Pappa2 allele was present
in the pregnancy, and no interaction between Mmp9 and
Pappa2 (Table 4; Fig. 3). Male fetuses were heavier than
female fetuses and had heavier placentae. The number of
Mmp9−/− toMmp9+/− conceptuses did not differ from the
expected 1:1 ratio (76 Mmp9−/− vs. 73 Mmp9+/−; χ21 =
0.06; P = 0.81).
We also studied fetuses at G18, in case growth restric-
tion was more apparent later in pregnancy. As at G16,
the average fetal mass and average placental mass did
not differ between Mmp9−/− and other females, and was
not affected by whether at least one wild-type Pappa2
allele was present or the interaction between these two
factors, controlling for the number of fetuses (Table 3;
Fig. 2). Average fetal mass tended to be lighter in
Mmp9−/− females but this was marginally
non-significant (P = 0.08, Table 3). Considering only
pregnancies segregating at Mmp9, Mmp9−/− fetuses were
lighter than their Mmp9+/− and Mmp9+/+ siblings, but
there was no effect of whether a wild-type Pappa2 allele
was present in the pregnancy, and no interaction
Fig. 1 Effect of Mmp9 and Pappa2 deletion on the number of fetuses, including females collected at either G16 or G18
Table 3 Effects of Mmp9 and Pappa2 deletion on average fetal mass and average placental mass
Term in model
Mmp9 Pappa2 Mmp9*Pappa2 interaction Number of fetuses
G16
F1,36 P F1,36 P F1,36 P F1,36 P
Average fetal mass 0.89 0.35 0.44 0.51 0.04 0.84 6.51 0.02
Average placental mass 3.50 0.07 0.82 0.37 0.01 0.94 10.76 0.002
G18
F1,15 P F1,15 P F1,15 P F1,15 P
Average fetal mass 3.41 0.08 1.13 0.31 0.03 0.86 2.08 0.17
Average placental mass 0.61 0.45 1.00 0.33 0.00 0.98 1.11 0.31
Statistics are from general linear models including effects of Mmp9 deletion (mating types 0 and 1 compared with others), Pappa2 deletion (whether the cross
included at least one functional Pappa2 allele or not), the interaction between these two factors, and the number of fetuses as a covariate
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Fig. 2 Effect of Mmp9 and Pappa2 deletion on fetal weight at G16 (upper panels) and G18 (lower panels)
Table 4 Effects of Mmp9 and Pappa2 deletion on fetal mass and placental mass in pregnancies segregating for Mmp9
Term in model
Mmp9 Pappa2 Mmp9*Pappa2 interaction Number of fetuses Sex of fetus
G16
F1,16 P F1,18 P F1,16 P F1,18 P F1,15 P
Fetal mass 9.69 0.007 0.07 0.80 0.40 0.54 2.97 0.10 14.72 0.002
Placental mass 12.63 0.003 0.06 0.80 0.01 0.91 5.12 0.04 31.08 0.0001
G18
F1,10 P F1,11 P F1,10 P F1,11 P F1,11 P
Fetal mass 9.53 0.012 0.59 0.46 0.03 0.88 7.24 0.02 1.06 0.32
Placental mass 0.81 0.39 1.13 0.31 1.26 0.29 4.49 0.06 17.82 0.0014
These analyses included multiple conceptuses per dam, and so statistics are from repeated measures analyses (with dam as a random factor), including effects of
Mmp9 genotype of conceptus (Mmp9−/− vs. Mmp9+/− and Mmp9+/+), Pappa2 deletion (whether the cross included at least one functional Pappa2 allele or not), the
interaction between these two factors, fetal sex, and the number of fetuses as a covariate
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between Mmp9 and Pappa2 (Table 4; Fig. 3). There was
no effect of Mmp9 genotype on placental weight. As at
G16, male fetuses had heavier placentae than female fe-
tuses. The genotype ratios did not differ from the ex-
pected Mendelian ratios in litters segregating for 2
genotypes (16 Mmp9−/−: 9 Mmp9+/−; χ21 = 1.96; P = 0.16)
or three genotypes (26 Mmp9−/−: 40 Mmp9+/−: 12
Mmp9+/+; χ21 = 5.08; P = 0.08). Though non-significant,
the trend was for an excess of Mmp9−/− conceptuses.
At G16, we observed little effect of Mmp9 deficiency
on the areas of the labyrinth, junctional zone or decidua,
either in absolute terms or in terms of each component
as a percentage of the total area (Table 5; Figs. 4 and 5).
There was generally no interaction between Mmp9 defi-
ciency and whether at least one wild-type Pappa2 allele
was present (Table 5; Fig. 4), although Mmp9−/− placen-
tae from Mmp9−/− dams with no Pappa2 had slightly
smaller decidua area, when measured as a percentage of
the total area (Table 5; Fig. 4). Pregnancies with no
Pappa2 had smaller deciduas in absolute terms, and had
larger labyrinths and smaller deciduas as a percentage of
the total area, compared to pregnancies where at least
one wild-type Pappa2 allele was present (Table 5; Fig. 4).
Placentae of male fetuses had larger junctional zone
Fig. 3 Effect of Mmp9 and Pappa2 deletion on fetal weight at G16 (left) and G18 (right) in pregnancies segregating at Mmp9. Open symbols are
Mmp9−/− fetuses and solid symbols are their Mmp9+/− and Mmp9+/+ siblings. Error bars are pooled per Mmp9 genotype (i.e., pooling Pappa2 genotype)
Table 5 Effects of Mmp9 and Pappa2 deletion on the areas of the labyrinth, junctional zone and decidua, either in absolute terms,
or as a percentage of total area
Term in model
Mmp9a Pappa2 Mmp9*Pappa2 interaction Sex of fetus
F2,28 P F1,28 P F2,28 P F1,20 P
Absolute
Labyrinth 0.20 0.82 0.00 0.98 1.64 0.21 0.10 0.75
Junctional Zone 0.38 0.69 1.93 0.18 0.69 0.51 14.76 0.001b
Decidua 3.17 0.06 7.89 0.01 2.62 0.09 2.90 0.10
Percentage of total
Labyrinth 1.15 0.33 6.89 0.01 1.80 0.18 15.01 0.001b
Junctional Zone 1.41 0.26 0.79 0.38 0.04 0.96 11.63 0.003b
Decidua 4.10 0.03 6.97 0.01 3.96 0.03 0.00 0.98
These analyses included multiple conceptuses per dam, and so statistics are from repeated measures analyses (with dam as a random factor), including effects of
Mmp9 group, Pappa2 deletion (whether the cross included at least one functional Pappa2 allele or not), the interaction between these two factors, and fetal sex
aIn these analyses, there were three Mmp9 groups: Mmp9−/− placentae from Mmp9−/− dams, Mmp9−/− placentae from Mmp9+/− dams, and Mmp9+/+ placentae
from Mmp9+/+ dams
bArea of the junctional zone, both absolute and as a percentage of the total area, was larger in males than females, while the area of the labyrinth as a
percentage of the total was smaller in males
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Fig. 4 Effect of Mmp9 and Pappa2 deletion on the areas of the labyrinth, junctional zone and decidua in absolute terms (upper panels) and as a
percentage of the total area (lower panels). Open symbols are pregnancies without a functional Pappa2 allele and solid symbols are pregnancies
with at least one functional Pappa2 allele. Error bars are from repeated measures analyses (with dam as a random factor), including effects of
Mmp9 group, Pappa2 deletion, the interaction between these two factors, and fetal sex
Fig. 5 Representative images of G16 placental sections from Mmp9−/− placentae from Mmp9−/− dams and Mmp9+/+ placentae from Mmp9+/+
dams, with and without Pappa2, showing the outlined labyrinth (L), junctional zone (J) and decidua (D). All placentae are from female fetuses
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areas in absolute terms and, as a percentage of the total
area, had larger junctional zones and smaller labyrinths.
The previous report of Mmp9 deletion mice [24] de-
scribed reduced serum VEGF levels in Mmp9−/− fe-
males. We analysed VEGF levels at G16 in a subset of
pregnancies of Mmp9−/− and Mmp9+/+ females, all with
at least one wild-type Pappa2 allele. VEGF levels did
not differ between Mmp9−/− and Mmp9+/+ females
(F1,10 = 0.12; P = 0.73), but were positively related with
the number of conceptuses (F1,10 = 13.70; P = 0.004;
Fig. 6).
Discussion
In humans, placental PAPP-A2 is upregulated in pre-
eclampsia [3–7] and fetal growth restriction [8]. However,
deletion of Pappa2 in mice has little effect on pregnancy
outcome [16, 21], suggesting that the upregulation of
PAPP-A2 in human pregnancy complications may repre-
sent a compensatory response [10, 22, 23]. If PAPP-A2 is
important in compensating for placental insufficiency, it
would be expected that its absence would exacerbate the
effects of placental dysfunction. Previously, Mmp9 defi-
ciency has been reported to cause placental abnormalities
resulting in growth restriction [24]. We observed that
Mmp9−/− fetuses were lighter than Mmp9+/− siblings, but
this difference was not exacerbated by deletion of Pappa2.
Therefore, our results do not provide evidence that
PAPP-A2 contributes to placental mechanisms that com-
pensate for poor fetal growth.
Surprisingly, we found no effect of Mmp9 deletion,
with or without deletion of Pappa2, on fertility, fecund-
ity, pregnancy loss, fetal loss or placental structure.
While the publication describing Mmp9 deletion as a
model of preeclampsia and intrauterine growth
restriction reported “as much as a 50% reduction in litter
size” [24], no data were presented, and the original re-
port of Mmp9 deletion described a much more modest
reduction in litter size (1.6 pups) [27]. In our experi-
ments, Mmp9−/− females were compared with control
siblings, and no experimental females were daughters of
Mmp9−/− females. It is therefore possible that by
avoiding maternal effects of Mmp9 deletion, the severity
of the deletion was reduced; whether previous reports
[24, 27] used our breeding scheme is not clear.
The previous report of the effects of Mmp9 deficiency
on pregnancy also reported reduced levels of VEGF in the
maternal circulation [24]. VEGF influences placental angio-
genesis, and maternal circulating VEGF levels are reduced
in preeclamptic human pregnancies [28]. While there was
no effect of Mmp9 deficiency on circulating maternal
VEGF in the present study, we found a positive association
between VEGF levels and the number of conceptuses. The
previous report of reduced VEGF in Mmp9−/− females [24]
may therefore have been due to reduced numbers of con-
ceptuses, rather than to placental pathology.
In addition to some modest effects of Mmp9 and
Pappa2 deletion, we observed more robust differences
between the sexes in fetal mass, placental mass, and pla-
cental structure at G16, as well as placental mass at
G18. These differences may reflect sex-specific strategies
for fetal growth and placental function [29] with poten-
tial long term effects on offspring health [30].
Conclusions
Previous work reported that deletion of Mmp9 reduced
pregnancy rates and implantation success following em-
bryo transfer, decreased litter size, and increased rates of
fetal demise and growth restriction [24]. In contrast, we
found only modest effects of Mmp9 deletion on fetal
growth, and found no effects on the number of fetuses, the
number of putative embryo resorptions, or female fertility
(number of matings required to achieve pregnancy, the
proportion of females that became pregnant, or the num-
ber of females with failed matings). The difference in re-
sults between our study and previous work may have been
due to our experimental design, which compared Mmp9−/
− females with control siblings and thus avoided confound-
ing maternal effects. The effects of Mmp9 deficiency were
not exacerbated by the deletion of Pappa2, and therefore
our results do not support the hypothesis that PAPP-A2
upregulation in human pregnancy complications repre-
sents a compensatory response to ameliorate placental
growth and development. Our results provide insight into
the role of PAPP-A2 dysregulation in devastating preg-
nancy complications, which may inform the use of this
protein as an early biomarker of placental health [9, 10].
Our work also serves as a caution regarding the use of
Mmp9 deficiency as a model of these complications.
Fig. 6 Relationship between number of fetuses and VEGF levels in
the maternal circulation of Mmp9−/− dams (open symbols) and
Mmp9+/+ dams (solid symbols) at G16. All pregnancies have at least
one functional copy of Pappa2
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